Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Beta-Secretase: Not So Fast? | Main | Little, Big »

May 18, 2007

But Enough About You

Email This Entry

Posted by Derek

Over at Nature's Sceptical Chymist blog they have a Friday interview feature, and this week you can see them interrogate me. (The blog's name is lifted from Robert Boyle, one that I liked so much that I also wrote it on the front of one of my undergraduate lab notebooks.) Note: I had this post up for a couple of hours attributing the title to Robert Hooke instead. It was early in the morning, really.)

Comments (9) + TrackBacks (0) | Category: Blog Housekeeping


COMMENTS

1. Palo on May 18, 2007 11:36 AM writes...

Way to go, Derek, the guy just blamed you for the cost of medications...

Permalink to Comment

2. rcyran on May 18, 2007 12:58 PM writes...

Way, way OT

Glad to hear your busy - job search near an end?

Anyway, I have a puzzle that might interest you or some readers. My friend's mixed-breed dog developed a slow growing malignant tumour (hemangiopericytoma). Apparently, this occurs more frequently in mixed-breed dogs than in almost any purebreed. This fact struck me as really odd.

The few hypotheses I could think of don't really stack up
-genetic bottlenecks somehow reduce incidence?
-common heritage of mixes? (although she's part pitbull like most mixes, that breed isn't high risk
- mutts get more viral infections from living on street?

Stats: ttp://cal.vet.upenn.edu/derm2/tables/mhemperi/Cb.htm

Permalink to Comment

3. JSinger on May 18, 2007 2:07 PM writes...

rcyran:

Some kind of trans-interaction where different breeds fix on different combinations of alleles that are mutually incompatible?

Unlikely, but the phenomenon you're trying to explain is atypical, so...

Permalink to Comment

4. TNC on May 18, 2007 3:06 PM writes...

Steely Dan? I would not have figured you for a classic rock-type.

Permalink to Comment

5. KJW on May 18, 2007 3:57 PM writes...

"Steely Dan? I would not have figured you for a classic rock-type."

Ditto!

Permalink to Comment

6. Still Scared of Dinoaurs on May 18, 2007 8:12 PM writes...

Yeah, I had you pegged as the Black Sabbath, Vivaldi, Perry Como type, too.

Permalink to Comment

7. Still Scared of Dinoaurs on May 18, 2007 8:18 PM writes...

And, re TNC's earlier comment and while we're on the topic of "fun with punctuation" (which we weren't): Do you consider yourself more of the classic-rock type or the classic rock-type?

Jes wunnerin...and remember, they're not mutually exclusive.

Permalink to Comment

8. Derek Lowe on May 18, 2007 8:33 PM writes...

Oh, there are a lot of overcerebral types who like old Steely Dan stuff. All those odd chord changes and studio perfectionism, y'know. And as for the comment on drug prices, that was from me. The Nature folks asked for a line or two of biography, and that's what I sent 'em. . .

Permalink to Comment

9. BCP on May 18, 2007 11:39 PM writes...

Nice interview, Derek. Interesting that no-one's mentioning Bach -- talk about chord changes; and I'm sure Johann would have been a studio perfectionist himself. I blame the beard/black sweater combo picture for the Black Sabbath associations from SSoD.

I have my fingers crossed for you with regards your future employment. As a pharma guy with (sheesh) 15yrs under my belt, I'm rooting for you whilst seeing my own career flash before my eyes. Given your comments, I would imagine that working for the man is a more difficult proposition for you to swallow these days...

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern